JP2022517698A - インテグリンαｖβ３に特異的な二環式ペプチドリガンド - Google Patents
インテグリンαｖβ３に特異的な二環式ペプチドリガンド Download PDFInfo
- Publication number
- JP2022517698A JP2022517698A JP2021563434A JP2021563434A JP2022517698A JP 2022517698 A JP2022517698 A JP 2022517698A JP 2021563434 A JP2021563434 A JP 2021563434A JP 2021563434 A JP2021563434 A JP 2021563434A JP 2022517698 A JP2022517698 A JP 2022517698A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- sar
- peptide ligand
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(CCC(NC1CC(CCCC2)CCC2CC1)=O)SSCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(*)=CC=C[C@]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)[C@]3(C)O[C@]3[C@](C)[C@]1OC2=O)=O)=O Chemical compound CC(CCC(NC1CC(CCCC2)CCC2CC1)=O)SSCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(*)=CC=C[C@]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)[C@]3(C)O[C@]3[C@](C)[C@]1OC2=O)=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1900528.9 | 2019-01-15 | ||
| GBGB1900528.9A GB201900528D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for integrin AVB3 |
| PCT/GB2020/050072 WO2020148528A1 (en) | 2019-01-15 | 2020-01-15 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517698A true JP2022517698A (ja) | 2022-03-09 |
| JPWO2020148528A5 JPWO2020148528A5 (https=) | 2023-01-25 |
| JP2022517698A5 JP2022517698A5 (https=) | 2023-01-25 |
Family
ID=65528176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563434A Pending JP2022517698A (ja) | 2019-01-15 | 2020-01-15 | インテグリンαｖβ３に特異的な二環式ペプチドリガンド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220119488A1 (https=) |
| EP (1) | EP3965892A1 (https=) |
| JP (1) | JP2022517698A (https=) |
| CN (1) | CN113613728A (https=) |
| GB (1) | GB201900528D0 (https=) |
| WO (1) | WO2020148528A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| US12551567B2 (en) | 2018-12-21 | 2026-02-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for PD-L1 |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| IL300248A (en) | 2020-08-03 | 2023-03-01 | Bicycletx Ltd | peptide-based linkers |
| BR102021016135A2 (pt) * | 2021-08-16 | 2023-02-23 | Novageia Biotecnologia Ltda | Antagonistas miméticos macrocíclicos com atividade biológica, seus usos e composições |
| CN114656525B (zh) * | 2022-04-25 | 2024-02-02 | 合肥师范学院 | 用于癌细胞整合素的rgd环肽及其在制备肿瘤药物中的应用 |
| WO2026002154A1 (en) * | 2024-06-27 | 2026-01-02 | Syneron Opal | Cell penetrating peptide compounds and using thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018502825A (ja) * | 2014-10-29 | 2018-02-01 | バイサイクル・セラピューティクス・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| WO2019002842A1 (en) * | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| WO2019243329A1 (en) * | 2018-06-22 | 2019-12-26 | Bicycletx Limited | PEPTIDE LIGANDS FOR BINDING TO INTEGRIN ανβ3 |
| WO2020148527A1 (en) * | 2019-01-15 | 2020-07-23 | Bicycletx Limited | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| DK1844337T3 (da) | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Bindingsforbindelser, immunogene forbindelser og peptidmimetika |
| AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| WO2011079015A1 (en) * | 2009-12-21 | 2011-06-30 | The Regents Of The University Of California | Rgd-containing cyclic peptides |
-
2019
- 2019-01-15 GB GBGB1900528.9A patent/GB201900528D0/en not_active Ceased
-
2020
- 2020-01-15 US US17/422,938 patent/US20220119488A1/en not_active Abandoned
- 2020-01-15 EP EP20701836.7A patent/EP3965892A1/en not_active Withdrawn
- 2020-01-15 JP JP2021563434A patent/JP2022517698A/ja active Pending
- 2020-01-15 CN CN202080020233.1A patent/CN113613728A/zh active Pending
- 2020-01-15 WO PCT/GB2020/050072 patent/WO2020148528A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018502825A (ja) * | 2014-10-29 | 2018-02-01 | バイサイクル・セラピューティクス・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| WO2019002842A1 (en) * | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| WO2019243329A1 (en) * | 2018-06-22 | 2019-12-26 | Bicycletx Limited | PEPTIDE LIGANDS FOR BINDING TO INTEGRIN ανβ3 |
| WO2020148527A1 (en) * | 2019-01-15 | 2020-07-23 | Bicycletx Limited | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3 |
Non-Patent Citations (1)
| Title |
|---|
| REBOLLO, IR ET AL.: "Phage display libraries of differently sized bicyclic peptides", MEDCHEMCOMM, vol. 4, JPN6024000349, 2013, pages 145 - 150, ISSN: 0005385968 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201900528D0 (en) | 2019-03-06 |
| CN113613728A (zh) | 2021-11-05 |
| US20220119488A1 (en) | 2022-04-21 |
| EP3965892A1 (en) | 2022-03-16 |
| WO2020148528A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517698A (ja) | インテグリンαｖβ３に特異的な二環式ペプチドリガンド | |
| JP2022518210A (ja) | インテグリンαｖβ３に特異的な二環式ペプチドリガンド | |
| JP2022517442A (ja) | Ｃａｉｘに特異的な二環式ペプチドリガンド | |
| JP2022514687A (ja) | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド | |
| JP2022518695A (ja) | Ｃａｉｘに特異的な二環式ペプチドリガンド | |
| JP2022514255A (ja) | Ｐｓｍａに特異的な二環式ペプチドリガンド | |
| JP2022514618A (ja) | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド | |
| JP2022513223A (ja) | Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド | |
| JP2022517399A (ja) | Ｃｄ３８に特異的な二環式ペプチドリガンド | |
| JP2022512478A (ja) | Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド | |
| JP2022517040A (ja) | Ｃｄ３８に特異的な二環式ペプチドリガンド | |
| JP2022532134A (ja) | Ｏｘ４０に特異的な二環式ペプチドリガンド | |
| JP2021506936A (ja) | ＥｐｈＡ２に特異的な二環ペプチドリガンド | |
| JP2021507909A (ja) | ＥｐｈＡ２に特異的な二環ペプチドリガンド | |
| US20210147485A1 (en) | Peptide ligands for binding to integrin | |
| JP2022544246A (ja) | 修飾された多量体二環式ペプチドリガンド | |
| JP2020529427A (ja) | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド | |
| JP2022513806A (ja) | Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド | |
| JP2022515720A (ja) | Ｉｌ－１７に特異的な二環式ペプチドリガンド | |
| CN117203219A (zh) | 特异性针对p-选择素的双环肽配体 | |
| JP2022515721A (ja) | ＦＡＰαに特異的な二環式ペプチドリガンド | |
| JP2023506874A (ja) | Ｉｌ－１７に特異的な二環式ペプチドリガンド | |
| JP2023506270A (ja) | Ｉｌ－１７に特異的な二環式ペプチドリガンド | |
| JP2023507134A (ja) | Ｉｌ－１７に特異的な二環式ペプチドリガンド | |
| EA046810B1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230112 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240806 |